Y Richard Wang

Summary

Affiliation: Temple University
Country: USA

Publications

  1. ncbi Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Ann Surg 251:51-8. 2010
  2. ncbi Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelpia, PA 19140, USA
    Arch Intern Med 167:141-7. 2007
  3. ncbi Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    Diabetes Care 30:49-52. 2007
  4. ncbi Trends of Heller myotomy hospitalizations for achalasia in the United States, 1993-2005: effect of surgery volume on perioperative outcomes
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Am J Gastroenterol 103:2454-64. 2008
  5. ncbi Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy
    Daniel W Cassilly
    Gastrointestinal Section, Department of Medicine, Temple University, Philadelphia, PA 19140, USA
    Digestion 78:144-51. 2008
  6. ncbi High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
    J Sanford Schwartz
    Department of Medicine, Leonard Davis Institute of Health Economics, Wharton School, Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 9:417-24. 2003
  7. ncbi The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104-6218, USA
    Health Econ 14:269-92. 2005
  8. ncbi Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
  9. ncbi The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
  10. ncbi The quantity and quality of worldwide new drug introductions, 1982-2003
    Henry G Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:452-60. 2006

Collaborators

Detail Information

Publications12

  1. ncbi Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, PA 19140, USA
    Ann Surg 251:51-8. 2010
    ..The purpose of this study was to quantify the time trends of hospitalizations and operations for PUD in the United States (US) since 1993...
  2. ncbi Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelpia, PA 19140, USA
    Arch Intern Med 167:141-7. 2007
    ..Hypertension guidelines in the United States tend to have more aggressive treatment recommendations than those in European countries...
  3. ncbi Lack of effect of guideline changes on hypertension control for patients with diabetes in the U.S., 1995-2005
    Y Richard Wang
    Department of Medicine, Temple University Hospital, Philadelphia, PA 19140, USA
    Diabetes Care 30:49-52. 2007
    ..S. using patients without diabetes as the control group for the time trend...
  4. ncbi Trends of Heller myotomy hospitalizations for achalasia in the United States, 1993-2005: effect of surgery volume on perioperative outcomes
    Y Richard Wang
    Department of Medicine, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA
    Am J Gastroenterol 103:2454-64. 2008
    ..We aimed to study the trends of Heller myotomy and the relationship between surgery volume and perioperative outcomes...
  5. ncbi Symptoms of gastroparesis: use of the gastroparesis cardinal symptom index in symptomatic patients referred for gastric emptying scintigraphy
    Daniel W Cassilly
    Gastrointestinal Section, Department of Medicine, Temple University, Philadelphia, PA 19140, USA
    Digestion 78:144-51. 2008
    ..The aim of this study was to correlate symptoms using the GCSI with delayed gastric emptying (DGE) in symptomatic patients referred for gastric emptying scintigraphy (GES)...
  6. ncbi High- versus low-dose angiotensin converting enzyme inhibitor therapy in the treatment of heart failure: an economic analysis of the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
    J Sanford Schwartz
    Department of Medicine, Leonard Davis Institute of Health Economics, Wharton School, Center for Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, USA
    Am J Manag Care 9:417-24. 2003
    ..CONCLUSIONS: Cost savings from fewer heart failure hospitalizations offset higher ACE inhibitor costs in the high-dose group. The improved clinical outcomes were achieved without increased treatment costs...
  7. ncbi The impact of price regulation on the launch delay of new drugs--evidence from twenty-five major markets in the 1990s
    Patricia M Danzon
    Health Care Systems Department, The Wharton School, University of Pennsylvania, Philadelphia, 19104-6218, USA
    Health Econ 14:269-92. 2005
    ..Controlling for expected price and volume, country effects for the likely parallel export countries are significantly negative...
  8. ncbi Price competition in the Chinese pharmaceutical market
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals 1800 Concord Pike, Wilmington, DE, 19850 5437, USA
    Int J Health Care Finance Econ 6:119-29. 2006
    ..Policy changes that encourage bioequivalent local products and accelerate global product approvals will enhance price competition in China...
  9. ncbi The prevalence of diagnosed cutaneous manifestations during ambulatory diabetes visits in the United States, 1998-2002
    Y Richard Wang
    Public Policy Department, Astra Zeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Dermatology 212:229-34. 2006
    ..The prevalence of diabetes has been rapidly increasing. Previous reports indicated that diabetics are prone to certain cutaneous diseases...
  10. ncbi The quantity and quality of worldwide new drug introductions, 1982-2003
    Henry G Grabowski
    Department of Economics, Duke University, Durham, North Carolina, USA
    Health Aff (Millwood) 25:452-60. 2006
    ..S. firms overtook their European counterparts in innovative performance or the introduction of first-in-class, biotech, and orphan products. The United States also became the leading market for first launch...
  11. ncbi Screening and treatment of hypercholesterolemia for prevention of coronary heart disease
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19850, USA
    Manag Care Interface 19:25-9. 2006
    ..Drug therapy recommendation also decreasedwith greater NCEP risk. Despite improvements, underscreening and undertreatment of hypercholesterolemia persists in outpatient visits...
  12. ncbi Difference in the use of preventive services between fee-for-service plans and HMOs: is more better?
    Y Richard Wang
    Public Policy Department, AstraZeneca Pharmaceuticals, Wilmington, Del 19850 5437, USA
    Am J Manag Care 9:293-301. 2003
    ....